Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
Q. M. Hanson, K. M. Wilson, M. Shen, Z. Itkin, R. T. Eastman, P. Shinn, M. D. Hall
The paper develops an AlphaLISA assay to measure SARS-CoV-2 spike RBD-ACE2 binding and identifies 25 drug candidates that disrupt this interaction.
bioRxiv · Jun 16, 2020Biochemistry